ValuEngine upgraded shares of Medpace (NASDAQ:MEDP) from a hold rating to a buy rating in a research note issued to investors on Thursday morning.

A number of other equities research analysts also recently weighed in on MEDP. BidaskClub raised shares of Medpace from a buy rating to a strong-buy rating in a research report on Wednesday, September 12th. SunTrust Banks started coverage on shares of Medpace in a report on Monday, September 17th. They issued a hold rating and a $63.00 price objective for the company. Finally, Zacks Investment Research upgraded shares of Medpace from a hold rating to a buy rating and set a $54.00 price objective for the company in a report on Thursday, November 1st. Five research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Medpace has a consensus rating of Buy and a consensus price target of $44.43.

Shares of Medpace stock opened at $60.14 on Thursday. The stock has a market capitalization of $2.08 billion, a PE ratio of 39.57, a P/E/G ratio of 1.26 and a beta of 1.61. The company has a current ratio of 0.66, a quick ratio of 0.66 and a debt-to-equity ratio of 0.25. Medpace has a 1 year low of $31.75 and a 1 year high of $65.09.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Thursday, November 1st. The company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.63 by $0.04. Medpace had a net margin of 10.84% and a return on equity of 15.86%. The business had revenue of $179.00 million during the quarter, compared to the consensus estimate of $175.07 million. During the same quarter in the prior year, the firm earned $0.40 EPS. The company’s revenue for the quarter was up 44.4% compared to the same quarter last year. Sell-side analysts forecast that Medpace will post 2.51 earnings per share for the current year.

Several institutional investors have recently bought and sold shares of MEDP. Vanguard Group Inc boosted its holdings in shares of Medpace by 63.6% in the third quarter. Vanguard Group Inc now owns 2,897,702 shares of the company’s stock valued at $173,601,000 after acquiring an additional 1,126,649 shares in the last quarter. Vanguard Group Inc. lifted its stake in Medpace by 63.6% during the third quarter. Vanguard Group Inc. now owns 2,897,702 shares of the company’s stock valued at $173,601,000 after purchasing an additional 1,126,649 shares during the last quarter. BlackRock Inc. lifted its stake in Medpace by 42.1% during the third quarter. BlackRock Inc. now owns 2,282,063 shares of the company’s stock valued at $136,719,000 after purchasing an additional 676,396 shares during the last quarter. Fuller & Thaler Asset Management Inc. acquired a new stake in Medpace during the third quarter valued at approximately $37,292,000. Finally, Renaissance Technologies LLC lifted its stake in Medpace by 131.6% during the third quarter. Renaissance Technologies LLC now owns 784,900 shares of the company’s stock valued at $47,023,000 after purchasing an additional 446,000 shares during the last quarter. Institutional investors and hedge funds own 67.54% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

See Also: What is a put option?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.